Prevalence of Helicobacter pylori primary resistance to antimicrobial agents in Poland and around the world;Wystȩpowanie pierwotnej oporności Helicobacter pylori na leki przeciwbakteryjne w polsce i na świecie

Postepy Mikrobiologii

Volumn 48, Issue 1, 2009, Pages 31-41

  Karczewska, Elzbieta ^a   Wojtas, Izabela ^a   Budak, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antibiotics; Chemiotherapeutics; Helicobacter pylori; Resistance; Treatment

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; POLAND; PREVALENCE; REVIEW;

HELICOBACTER PYLORI;

EID: 66649124292     PISSN: 00794252     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Aiba Y., Suzuki N., Kabir A.M., Takagi A., Koga Y.: Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am. J. Gastroenterol. 93, 2097-2101 (1998) (Pubitemid 29076857)
2. Ando T., Goto Y., Maeda O., Watanabe O., Ishiguro K., Goto H.: Causal role of Helicobacter pylori infection in gastric cancer. World J. Gastroenterol. 12, 181-186 (2006) (Pubitemid 43336914)
3. Antos D., E. Bayerdörffer i wsp.: 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter, 11, 39-45 (2006)
4. Baglan P.H., Bozdayi G., Ozkan M., Ahmed K., Bozdayi A.M., Ozden A.: Clarithromycin resistance prevalence and Icea gene status in Helicobacter pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. J. Microbiol. 44, 409-416 (2006) (Pubitemid 46657473)
5. Ba̧k-Romaniszyn L., Płaneta-Małecka I.: Przyczyny niepowodzenia eradykacji Helicobacter pylori. Ped. Wsp. Gastroent. Hep. Żyw. Dziecka, 6, 387-391 (2004)
6. Bogaerts P., Berhin C., Nizet H., Glupczynski Y.: Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter, 11, 441-445 (2006) (Pubitemid 44352615)
7. Boyanova L., M. Popova i wsp.: The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin. Microbiol. Infect. 8, 388-396 (2002) (Pubitemid 34993815)
8. Boyanova L., Z. Krastev i wsp.: Antimicrobial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years. J. Med. Microbiol. 55, 65-68 (2006) (Pubitemid 43031240)
9. Broutet N., Marais A., Lamouliatte H., Mascarel A., Samoyeau R., Salamon R., Megraud F.: cagA status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with nonulcer dyspepsia. J. Clin. Microbiol. 39, 1319-1322 (2001)
10. Brown L.M.: Helicobacter pylori: Epidemiology and routes of transmission. Epidemiol. Rev. 11, 283-297 (2000)
11. Bytzer P., O' Morain C.: Treatment of Helicobacter pylori. Helicobacter, 10, 40-46 (2005)
12. th European Congress of Clinical Microbiology and Infectious Diseases. Munich/Germany, 31 March-3 April 2007
13. Cianci R., Montalto M., Pandol F., Gasbarrini G.B., Cammarota G.: Third-line rescue therapy for Helicobacter pylori infection. World J. Gastroenterol. 12, 2313-2319 (2006)
14. Co E.M., Schiller N.L.: Resistance mechanisms in an in vitro-selected amoxicillin-resistant strain of Helicobacter pylori. Antimicrob. Agents Chemother. 50, 4174-4176 (2006)
15. Czerwonka-Szafarska M., Zielinska H., Parzȩcka M.: Zakażenie Helicobacter pylori- co wiemy i co wiedzieć powinniśmy. Klin. Ped. 12, 5020-5023 (2004)
16. Dailidiene D., Bertoli M.T., Miciuleviciene J., Mukhopadhyay A.K., Dailide G., Pascasio M.A., Kupcinskas L., Berg D.E.: Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Ant. Agents Chem. 46, 3940-3946 (2002)
17. Dzieniszewski J., Jarosz M.: Wytyczne postȩpowania leczniczego w infekcji Helicobacter pylori. Med. po Dypl. 13, 39-43 (2006)
18. Dzieniszewski J., M. Jarosz i Grupa Robocza PTG*: Postȩpowanie w zakażeniu Helicobacter pylori (rok 2004). Wytyczne opracowane przez Grupȩ Robocza̧ Polskiego Towarzystwa Gastroenterologii. Gastroenterol. Pol. 11, 41-48 (2004)
19. Dzierzanowska-Fangrat K., Rozynek E., Jozwiak P., Celinska-Cedro D., Madalinski K., Dzierzanowska D.: Primary resistance to clarithromycin in clinical strains of Helicobacter pylori isolated from children in Poland. Int. J. Antimicrob. Agents, 18, 387-390 (2001)
20. Dzierżanowska D.: Antybiotyki w praktyce ambulatoryjnej. Alfa-medica Press, Bielsko-Biała, 2005
21. Dzierżanowska-Fangrat K., D. Dzierżanowska i wsp.: Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study. Int. J. Antimicrob. Agents, 26, 230-234 (2005)
22. Eisig J.N., Silva F.M., Rodriguez T.N., Hashimoto C.L., Barbuti R.C.: A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease. Clinics, 60, 485-488 (2005)
23. European Helicobacter Pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut, 41, 8-13 (1997)
24. Gerrits M.M., Godoy A.P., Kuipers E.J., Ribeiro M.L., Stoof J., Mendonca S., van Vliet A.H., Pedrazzoli J.Jr, Kusters J.G.: Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori. Helicobacter, 11, 181-187 (2006) (Pubitemid 43736553)
25. Gerrits M.M., Schuijffel D., van Zwet A.A., Kuipers E.J., Vandenbroucke-Grauls C.M.J.E., Kusters J.G.: Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori. Antimicrob. Agents Chemother. 46, 2229-2233 (2002) (Pubitemid 34665920)
26. Gerrits M.M., van der Wouden E.J., Bax D.A., van Zwet A.A., van Vliet A.H.M., de Jong A., Kusters J.G., Thijs J.C., Kuipers E.J.: Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori. J. Med. Micobiol. 53, 1123-1128 (2004) (Pubitemid 40052496)
27. Glupczynski Y., Megraud F., Lopez-Brea M., Andersen L.P.: European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 20, 820-823 (2001) (Pubitemid 34020461)
28. Go M.F.: Diagnosis and treatment of Helicobacter pylori. Curr. Treat. Options Gastroenterol. 8, 163-174 (2005)
29. Godlewska R., Jagusztyn-Krynicka E.K.: Analiza czynników wirulencji Helicobacter pylori w świetle genomiki. Post. Mikrobiol. 42, 115-137 (2003)
30. Goldman K.J., Cockburn M.: The role of epidemiology in understanding the health effects of Helicobacter pylori. Epidemiology, 12, 266-271 (2001)
31. Gościniak G.: Przeciwciała w zakażeniach Helicobacter pylori. Rozprawa na stopień doktora habilitowanego. Akademia Medyczna, Wrocław, 2000
32. Gzyl A., Augustynowicz E., Dzierżanowska D., Rozynek E., Dura W., Celińska-Cedro D., Berg D.E.: Genotypes of Helicobacter pylori in Polish population. Acta Microbiol. Pol. 48, 261-275 (1999) (Pubitemid 30045880)
33. Hauck C.R.: Preparing the shot. Nature, 449, 798-799 (2007)
34. Heatley R.V.: Helicobacter pylori. Alfa-medica press, Bielsko-Biała, 1999
35. Howden C.W., Hunt R.H.: Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol. 93, 2330-2338 (1998)
36. Hryniewicz W., Meszaros J. (red.): Antybiotyki w profilaktyce i leczeniu zakażeń. Wydawnictwo Lekarskie PZWL, Warszawa, 2001
37. Iwańczak F., E. Vogtt i wsp.: Badania epidemiologiczne czȩstości wystȩpowania zakażenia Helicobacter pylori u dzieci w Polsce. Ped. Wsp. Gastroent. Hep. Żyw. Dziecka, 6, 345-350 (2004)
38. Jagusztyn-Krynicka E.K., Godlewska R., Łaniewski P.: Helicobacter pylori - patogen roku 2005. Kosmos, Probl. Nauk Biol. 54, 307-319 (2005)
39. nd Polish-Ukrainian Weigl Conference "Microbiology in the XXI century" Warsaw, 24-26 September 2007
40. Janssen M.J., Hendrikse L., de Boer S.Y., Bosboom R., de Boer W.A., Laheij R.J., Jansen J.B.: Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth. J. Med. 64, 191-195 (2006) (Pubitemid 43970920)
41. Jeong J.Y., Mukhopadhyay A.K., Akada J.K., Dailidiene D., Hoffman P.S., Berg D. E.: Role of FrxA and RdxA nitro-reductases of Helicobacter pylori in susceptibility and resistance to metronidazole. J. Bacteriol. 183, 5155-5162 (2001) (Pubitemid 32750944)
42. Kim J.M., Kim J.S., Jung H.C., Kim N., Kim Y.J., Song S.: Distribution of antibiotic MICs fox Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob. Agents Chemother. 48, 4843-4847 (2004) (Pubitemid 39577692)
43. Koivisto T.T., Rautelin H.I., Voutilainen M.E., Niemelä S.E., Heikkinen M., Sipponen P.I., Färkkilä M.A.: Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment. Pharmacol. Titer. 19, 1009-1017 (2004) (Pubitemid 38657382)
44. Konturek S.J.: Laureaci Nagrody Nobla z fizjologii i medycyny w roku 2005: Barry J. Marshall i Robin J. Warren. Med. po Dypl. 14, 1-6 (2005)
45. Kwok T., S. Backert i wsp.: Helicobacter exploits integrin for type IV secretion and kinase activation. Nature, 449, 862-866 (2007) (Pubitemid 47598611)
46. Łaszewicz W.: Wyniki badań nad zakażeniem Helicobacter pylori. Trans Humana, Białystok, 2004
47. Malfertheiner P., Megraud F., O' Morain C., Bazzoli F., El-Omar E., Graham D., Hunt R., Rokkas T., Vakil N., Kuipers E.J.: Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 56, 772-781 (2007) (Pubitemid 46854190)
48. Malfertheiner P., Megraud F., O' Morain C., Hungin A.P., Jones R., Axon A., Graham D.Y., Tytgat G.; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection- The Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Then 16, 167-180 (2002)
49. Marais A., Bilardi C., Cantet F., Mendz G.L., Megraud F.: Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res. Microbiol. 154, 137-144 (2003) (Pubitemid 36324505)
50. Marshall B.J., Warren J.R.: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration, Lancet, 1, 1311-1314 (1984) (Pubitemid 14111103)
51. th Europ. Congr. of Clin. Microbiol. and Infect. Dis. Munich/Germany, 31 March-3 April 2007
52. Megraud F., Lehn N., Lind T., Bayerdörffer E., O' Morain C., Spiller R., Unge P., van Zanten S.V., Wrangstadh M., Burman C.F.: Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 Study. Antimicrob. Agents Chem. 43, 2747-2752 (1999) (Pubitemid 29519559)
53. Megraud F.: H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut, 53, 1374-1384 (2004)
54. Megraud F.: Update on therapeutic options for Helicobacter pylori-related diseases. Curr. Infect. Dis. Rep. 7, 115-120 (2005)
55. Michetti P., Dorta G., Brassard D., Vouillamoz D., Schwitzer W., Felley C., Blum A.L., Porta N., Rouvet W., Corthesy-Theulaz J.: L. acidophilus supernatant as an adjuvant in the therapy of H. pylori in humans. Gastroenterology, 108, A166 (1995)
56. Nista E.C., Candelli M., Zocco M.A., Cremonini F., Ojetti V., Finizio R., Spada C., Cammarota G., Gasbarrini G., Gasbarrini A.: Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am. J. Gastroenterol. 101, 1985-1990 (2006)
57. Oleastro M., Menard A., Santos A., Lamouliatte H., Monteiro L., Barthelemy P., Megraud F.: Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J. Clin. Microbiol. 41, 397-402 (2003) (Pubitemid 36098606)
58. Paradowski L., Blachut K., Annabhani A.: Konsensus Maastricht 2005. Co nowego? Gastroenterol. Pol. 13, 335-336 (2006)
59. Perez-Perez G.I., Rothenbacher D., Brenner H.: Epidemiology of Helicobacter pylori infection. Helicobacter, 9, 1-6 (2004)
60. Petersen A.M., Gjode P., Vinge O.D., Jensen S., Krogfelt K.A.: Helicobacter pylori antimicrobial resistance and risk factors in Denmark 1998-2004: no need for concern? Helicobacter, 11, 208-211 (2006)
61. Płaneta-Małecka I., Ba̧k-Romaniszyn L., Plewińska E.M., Czkwianianc E., Seraficka A.: Rola probiotyków w leczeniu zakażenia Helicobacter pylori - doniesienie wstȩpne. Gastroenterol. Pol. 11, 219-222 (2004)
62. Rang H.P., Dale M.M., Ritter J.M.: Farmakologia kliniczna. Czelej Sp. z.o.o., Lublin, 2001.
63. Raport Uzgodnieniowy Maastricht III: Aktualne pogla̧dy na wykrywanie i leczenie zakażenia Helicobacter pylori. Med. Prakt. 7-8, 157-175 (2007)
64. Rożynek E., Dzierżanowska-Fangrat K., Celińska-Cedro D., Jóźwiak P., Madaliński K., Dzierżanowska D.: Primary resistance of Helicobacter pylori to antimicrobial agents in Polish children. Acta Microbiol. Pol. 51, 255-263 (2002)
65. Sheu B.S., Wu J.J., Lo C.Y., Wu H.W., Chen J.H., Lin Y.S., Lin M.D.: Impact of supplement with Lactobacillus and Bifidobacterium - containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 16, 1669-1675 (2002)
66. Tamura A., Kumai H., Nakamichi N., Sugiyama T., Deguchi R., Takagi A., Koga Y.: Suppression of Helicobacter pylori-induced interleukin-8 production in vitro and within the gastric mucosa by a live Lactobacillus strain. J. Gastroenterol. Hepatol. 21, 1399-1406 (2006) (Pubitemid 44154707)
67. Torres J., Camorlinga-Ponce M., Perez-Perez G., Madrazo-De la Garza A., Dehesa M., Gonzalez-Valencia G., Munoz O.: Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J. Clin. Microbiol. 39, 2677-2680 (2001) (Pubitemid 32606258)
68. Trieber C.A., Taylor D.E.: Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline. J. Bacteriol. 184, 2131-2140 (2002) (Pubitemid 34259662)
69. Van Doom L.J., Glupczynski Y., Kusters J.G., Megraud F., Midolo P., Maggi-Solca N., Queiroz D.M., Nouhan N., Stet E., Quint W.G.: Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob. Agents Chemother. 45, 1500-1504 (2001) (Pubitemid 32374124)
70. Van Doom L.J., Schneeberger P.M., Nouhan N., Plaisier A.P., Quint W.G.V., de Boer W.A.: Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut, 46, 321-326 (2000) (Pubitemid 30313381)
71. Van Zwet A.A., Vandenbroucke-Grauls C.M., Thijs J.C., van der Wouden E.J., Gerrits M.M., Kusters J.G.: Stable amoxicillin resistance in Helicobacter pylori. Lancet, 352, 1595 (1998)
72. Ziemniak W.: Praktyczne aspekty leczenia infekeji żoła̧ dkowej Helicobacter pylori. Med. po Dypl. 13, 69-74 (2006)
73. Życińska K., Wardyn K.A., Życiński Z.: Zakażenie Helicobacter pylori - współczesne pogla̧dy na diagnostykȩ i leczenie. Now. Klin. 9, 956-959 (2002)